Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer

Vassart, 1992, The thyrotropin receptor and the regulation of thyrocyte function and growth, Endocrine reviews, 13, 596

Brabant, 2008, Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets?, The Journal of clinical endocrinology and metabolism, 93, 1167, 10.1210/jc.2007-2228

Fiore, 2012, Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease, The Journal of clinical endocrinology and metabolism, 97, 1134, 10.1210/jc.2011-2735

Haymart, 2008, Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage, The Journal of clinical endocrinology and metabolism, 93, 809, 10.1210/jc.2007-2215

Wang, 1999, Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma, The Journal of clinical endocrinology and metabolism, 84, 4549

McGriff, 2002, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer, Annals of medicine, 34, 554, 10.1080/078538902321117760

Cooper, 1998, Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry, Thyroid: official journal of the American Thyroid Association, 8, 737, 10.1089/thy.1998.8.737

Diessl, 2012, Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma, Clinical endocrinology, 76, 586, 10.1111/j.1365-2265.2011.04272.x

Pacini, 2006, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, European journal of endocrinology/European Federation of Endocrine Societies, 154, 787, 10.1530/eje.1.02158

American Thyroid Association Guidelines Taskforce on Thyroid, 2009, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid: official journal of the American Thyroid Association, 19, 1167, 10.1089/thy.2009.0110

Borson-Chazot, 2008, Guidelines for the management of differentiated thyroid carcinomas of vesicular origin, Annales d'endocrinologie, 69, 472, 10.1016/j.ando.2008.10.002

Sugitani, 2010, Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial, The Journal of clinical endocrinology and metabolism, 95, 4576, 10.1210/jc.2010-0161

Danzi, 2012, Thyroid hormone and the cardiovascular system, The Medical clinics of North America, 96, 257, 10.1016/j.mcna.2012.01.006

Biondi, 1996, Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine, The Journal of clinical endocrinology and metabolism, 81, 4224

Abonowara, 2012, Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer, Clinical and investigative medicine Medecine clinique et experimentale, 35, E152, 10.25011/cim.v35i3.16591

Bauer, 2007, Thyroid hormone use, hyperthyroidism and mortality in older women, The American journal of medicine, 120, 343, 10.1016/j.amjmed.2006.04.034

Flynn, 2010, Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy, The Journal of clinical endocrinology and metabolism, 95, 186, 10.1210/jc.2009-1625

Gorka, 2013, Metabolic and clinical consequences of hyperthyroidism on bone density, International journal of endocrinology, 2013, 638727, 10.1155/2013/638727

Mikosch, 2003, Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment, Thyroid: official journal of the American Thyroid Association, 13, 347, 10.1089/105072503321669839

Lee, 2014, Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer, Annals of surgical treatment and research, 86, 55, 10.4174/astr.2014.86.2.55

Tournis, 2014, Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression, Clinical endocrinology

Bauer, 2001, Risk for fracture in women with low serum levels of thyroid-stimulating hormone, Annals of internal medicine, 134, 561, 10.7326/0003-4819-134-7-200104030-00009

Sugitani, 2011, Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study, Surgery, 150, 1250, 10.1016/j.surg.2011.09.013

Samuels, 2014, The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition, The Journal of clinical endocrinology and metabolism, 99, 843, 10.1210/jc.2013-3686

Moon, 2014, The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma, The Journal of clinical endocrinology and metabolism, 99, 3782, 10.1210/jc.2013-4454

Ito, 2012, TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy, European journal of endocrinology/European Federation of Endocrine Societies, 167, 373, 10.1530/EJE-11-1029

Jaracz, 2012, Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma, Journal of endocrinological investigation, 35, 760

Eustatia-Rutten, 2006, Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial, Clinical endocrinology, 64, 284, 10.1111/j.1365-2265.2006.02458.x

Botella-Carretero, 2003, Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma, Endocrine-related cancer, 10, 601, 10.1677/erc.0.0100601

Biondi, 2010, Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer, Thyroid: official journal of the American Thyroid Association, 20, 135, 10.1089/thy.2009.0311

McLeod, 2013, Controversies in primary treatment of low-risk papillary thyroid cancer, Lancet, 381, 1046, 10.1016/S0140-6736(12)62205-3

Rosen, 1998, Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate, The Journal of clinical endocrinology and metabolism, 83, 2324

Verburg, 2014, The Thyroid Axis ‘Setpoints’ are Significantly Altered After Long-Term Suppressive LT4 Therapy, Hormone and metabolic research=Hormon- und Stoffwechselforschung=Hormones et metabolisme, 46, 794, 10.1055/s-0034-1375678